This has justifiably attracteda great deal of attention in both academia and the industry, withseveral small-molecule inhibitors which can chemically reduce USP30activity in development.17−22 Significantly, the USP30 inhibitors MTX652 and MTX325 are currentlybeing tested in clinical trials for the treatment of acute kidneyinjury and PD.23 This evidence concerns the gene USP30 and Parkinson disease.